CABOMETYX
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Phone Number
(650) 837-7000Website
www.cabometyx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About CABOMETYX
Exelixis, Inc. specializes in developing and providing innovative therapies for cancer treatment, particularly CABOMETYX® (cabozantinib), which is prescribed for various cancer types including advanced kidney, liver, and differentiated thyroid cancers. The company offers comprehensive resources for patients and healthcare providers, including support services for insurance coverage and financial assistance. Designed primarily for US patients, the CABOMETYX patient website serves as a key information and support hub. Exelixis, Inc. is dedicated to enhancing patient care through educational resources and personalized treatment support.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CABOMETYX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at CABOMETYX
Click to see if CABOMETYX had a recent Job posting/layoffs
Funding: Get notified immidiatlly once CABOMETYX has new funding data
Product Launch: Get notified when CABOMETYX launches new products
Check out if CABOMETYX is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if CABOMETYX has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on CABOMETYX recently announced quarterly report
CABOMETYX, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to CABOMETYX
Compare insights from companies similar to CABOMETYX, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Company Profile Activity
Activity Insights
CABOMETYX is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CABOMETYX is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CABOMETYX.
CABOMETYX Tech Stack
A closer look at the technologies used by CABOMETYX
CABOMETYX News & Media
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. The sNDA is based on the final reExelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This settlement resolves two patent litigations brought by Exelixis in response to Cipla’s Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of CABOMETYX® (cabozantinib) tablets prior to the expiration of the applicable patents. The first case (Civil ActiOpdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
PRINCETON, N.J. & ALAMEDA, Calif.--(BUSINESS WIRE)---- $BMY #ASCO--Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial....Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (collectively Teva). This settlement resolves patent litigation brought by Exelixis in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of CABOMETYX® (cabozantinib) tablets prior to the expiration of the applicabl
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CABOMETYX
Sign Up For FreeTo access detailed company insights
Exelixis, Inc. specializes in developing and providing innovative therapies for cancer treatment, particularly CABOMETYX® (cabozantinib), which is prescribed for various cancer types including advanced kidney, liver, and differentiated thyroid cancers. The company offers comprehensive resources for patients and healthcare providers, including supp... Read More
